肝炎治療GL vs ADOPT
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
肝炎治療GL
This app provides a condensed version of the B and C Hepatitis treatment guidelines created by the Japan Society of Hepatology. It allows for easy checking of drug interactions and can be used offline. The app is suitable for physicians, healthcare professionals, and the general public involved in hepatitis care.
- B and C Hepatitis treatment guidelines digest
- Drug interaction checker
- Offline access
- Japanese and English language support
- Extracted key information and figures
Read full descriptionHide full description
日本肝臓学会にて作成された「B型肝炎治療ガイドライン」および「C型肝炎治療ガイドライン」のダイジェスト版アプリ(日本語、英語切り替え可能)です。2016年5月にC型肝炎治療薬と各種薬剤の相互作用を確認できる機能を追加しました。薬剤投与前に相互作用をきたす薬剤を服用していないかどうかを簡単に確認できます。 現在の日常臨床において重要と思われる記載、及び図表を抜粋しており、簡便で使用しやすい内容となっております。一度モバイルにダウンロードいただければ、オフライン環境でもご利用いただけます。肝炎診療に携わる医師・医療従事者、または一般の方々もご利用いただけます。 【動作確認機種】 iOS9.0以上搭載のiPhone4S以降、iPod touch(第5世代)以降 (動作確認機種以外では正常に動作しない場合があります。)
ADOPT
Read full descriptionHide full description
Adequate Operative Treatment for Liver Cirrhosis (ADOPT-LC) Score Using the Japanese nationwide database with more than 10 million patients, we developed a model for predicting in-hospital mortality of patients with surgical procedures (excluding liver resection or transplantation). This scoring system with simple parameters (patient age, Child-Pugh classification (A-C), Charlson Comorbidity Index, and estimated duration of anesthesia) was shown to provide higher predictive performance compared to Child-Pugh score (5-15 points) alone. By the use of this scoring system, this application software provides predicted in-hospital mortality calculated based on the 4 parameters you enter. I hope that this calculator may enable determination of whether surgery is warranted in patients with liver cirrhosis. This application software is developed or powered by Department of Gastroenterology (Liver Study Group), Department of Clinical Epidemiology and Health Economics at The University of Tokyo, and CureApp, Inc. 【Disclaimer】 The article for evidence used in this application is under submission. Some modifications may be added until publication.
Screenshots
Verdict
The clearest difference is update cadence: ADOPT at every 9 days against 肝炎治療GL's every 6 months. ADOPT also leads on iOS requirement (7.1 vs 12.0). On price, ads, in-app purchases and device support there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
肝炎治療GL ships an update every 6 months, ADOPT every 9 days. The most recent releases landed on September 22, 2026 and September 29, 2026 respectively.
| Parameter | 肝炎治療GL | ADOPT |
|---|---|---|
| Price | Free | Free |
| Update frequency | Every 6 months | Every 9 days — better |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Free | — |
| Devices | iPhone, iPad, iPod — better | iPhone, iPod |
| Requires iOS | 12.0 | 7.1 — better |
| Further details — not scored | ||
| Size | 67 MB | 10 MB |
| Age rating | 17+ | 17+ |
| Developer | Wiley Publishing Japan | CureApp, Inc. |
In-app purchases
肝炎治療GL
No in-app purchases
ADOPT
No in-app purchases









